Daunorubicin HCl

Catalog No.S3035 Synonyms: Daunomycin HCl

Daunorubicin HCl Chemical Structure

Molecular Weight(MW): 563.98

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay.
Targets
DNA synthesis [1]
(Cell-free assay)
20 nM(Ki)
In vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. [1] Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. [2] Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
P388 leukemia cell line NXHGUoJMS3m2b4TvfIlkyqCjc4PhfS=> MojpR49ueG:3bnSge4F{KGW4YXz1ZZRm\CCob4KgZ5l1d3SxeHnjbZR6KGGpYXnud5QhWDN6ODDs[ZVs\W2rYTDj[YxtKGyrbnWsJGlEPTB;MzDuUS=> MU[xNFQ4QTJ7Nx?=
HL60 cells NEfmdmZHfW6ldHnvckBie3OjeR?= NFLKSGlKdiC4aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDwdo9tcW[ncnH0bY9vKG:oIFjMOlAh[2WubIOsJGlEPTB;MD6wNFUh|ryP NX3WT2FEOTJ6N{e1PVM>
human epidermoid carcinoma cell line KB-3-1 Mn60R5l1d3SxeHnjxsBie3OjeR?= MkTKTY4hfmm2cn:gZ5l1d3SxeHnjJIFkfGm4aYT5JJdieyCndnHseYF1\WRidYPpcochfGinIHj1cYFvKGWyaXTldo1wcWRiY3HyZ4lvd22jIHPlcIwhdGmwZTDLRk0{NTFuIFnDOVA:PyCwTR?= NEW2N4EyOjR2M{e2Ny=>
human K562 cells NXjvdFM4S3m2b4TvfIlkyqCjc4PhfS=> NFGze3c4OiCq MkLHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{Bi\nSncjC3NkBpenNiYomgXHRVKGG|c3H5MEBIUTVyPUeuOEBvVQ>? NHH5bJczODV7MU[3PC=>
Dx5 w/PSC cell lines M3H0PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPUbIUh[2:vcH;1coQhf2G|IHX2ZYx2[XSnZDDmc5IhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGR5PSC5L2DTR{Bk\WyuIHzpcoV{KHW|aX7nJG1VXCCjc4PhfUwhUUN3ME2xOEBvVQ>? NFzFOmgyODZ7OES0PS=>
MDA MB 361(mammary carcinoma cell line) MWPDfZRwfG:6aXRCpIF{e2G7 NYTyNHdiXGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSg[o9zKGmwdILhZ4VtdHWuYYKgZ5l1d3SxeHnjbZR6KGGpYXnud5QhVUSDIF3CJFM3OSivYX3tZZJ6KGOjcnPpco9u[SClZXzsJIxqdmVrIHX4dJJme3OrbnegUIFkYiBqYnX0ZU1o[WyjY4Tvd4ll[XOnKTygTWM2OD1zNzDuUS=> NFvIO|YyODN7NUS5NC=>
human MDA-MB-231 cells M3P1TWN6fG:2b4jpZ:Kh[XO|YYm= NYDocHlvPzJiaB?= MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFIh|ryP NV\iN2pKOTl7NkiyOVg>
MES-SA uterine tumor cell lines NEjjRWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\sW5BIXGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCPRWOtV2EhfXSncnnu[UB1fW2xcjDj[YxtKGyrbnXzJJV{cW6pIF3UWEBie3OjeTygTWM2OD1yLkCyNUDPxE1? MV6xNFY6QDR2OR?=
murine L1210 leukemia cells M3;pVWZ2dmO2aX;uJIF{e2G7 MYjJcohq[mm2b4L5JIFkfGm4aYT5JJdieyCvZXHzeZJm\CCjZ3HpcpN1KG23cnnu[UBNOTJzMDDs[ZVs\W2rYTDj[YxteyxiSVO1NF0{OCCwTR?= NEDWb4k6PzN|NEiz
HL60 cells MU\GeY5kfGmxbjDhd5NigQ>? M4TldmlvKH[rdILvJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5lfWOnIHHwc5B1d3OrczDpckBJVDZyIHPlcIx{NCCDQ{WwQVAvODRizszN NWL2XpR5OTJ6N{e1PVM>
CCRF-CEM (human lymphoblastic leukemic) cells MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{\HcWlvKH[rdILvJIdzd3e2aDDpcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgR2NTTi2FRV2gLIh2dWGwIHz5cZBpd2KuYYP0bYMhdGW3a3XtbYMqKGOnbHzzMEBKTDVyPUCuNFQh|ryP NXTSSIZLPjl3MUC0PS=>
mouse NIH/3T3 cells MXvDfZRwfG:6aXRCpIF{e2G7 MlfhO|IhcA>? MnrlTY51emmwc3njJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHerbHSgeJlx\SCvb4Xz[UBPUUhxM2SzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yNESg{txO MVixPFk2PDB2MB?=
human prostate cancer HTB-81 cells NX;iXJpGS3m2b4TvfIlkyqCjc4PhfS=> M2fKV2N6fG:2b4jpZ4l1gSC2aHH0JINifXOnZDDhJFUxLSC{ZXT1Z5Rqd25iaX6gZYJ{d3KkYX7j[UBifCB2OUCgco0hcW5iaIXtZY4heHKxc4TheIUh[2GwY3XyJGhVSi16MTDj[YxteyC3c3nu[{BOXFNiYYPzZZktKEWFNUC9NE4xPThizszN NHPOemgyOTB{MEK4OS=>
human breast carcinoma line cells MX3GeY5kfGmxbjDhd5NigQ>? MU\jc41xd3WwZDD3ZZMhfGW|dHXkJIlvKH[rdILvJIZweiCrbnjpZol1cW:wIHHjeIl3cXS7IHHnZYlve3RiYTDz[Y5{cXSrdnWgbJVu[W5iYoLlZZN1KGOjcnPpco9u[SCuaX7lJINmdGy|LDDJR|UxRTBwME[g{txO M1\qdlkzPTh|NUG=
MCF-7 cells MlG2R5l1d3SxeHnjxsBie3OjeR?= NUD6elYxS2:vcH;1coQhf2G|IITld5Rm\CCob4KgbZR{KHSxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{hOS0ZvNzmsJGlEPTB;MD6wOkDPxE1? NWXS[pFrQTV2OEiyNC=>
human HT-29 cells NHfaflFEgXSxdH;4bYPDqGG|c3H5 NGjlO5Y4OiCq MkfrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVA:OC5yNzFOwG0> NWTwdVhzOTl7NkiyOVg>
human uterine sarcoma cell line MES-SA M3ntTWN6fG:2b4jpZ:Kh[XO|YYm= MWfJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KGW4YXz1ZZRm\CC3c3nu[{B1cGViaIXtZY4hfXSncnnu[UB{[XKlb33hJINmdGxibHnu[UBOTVNvU1GsJGlEPTB;MD6wO{DPxE1? MYexNlQ1Ozd4Mx?=
human MRC5 cells M3W0OnBzd2yrZnXyZZRqd25iYYPzZZk> MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2UQ{WgZ4VtdHNiYomgXHRVKGG|c3H5MEBKSzVyPUCuNFc5KM7:TR?= MV:yOVQ3PzJ7MR?=
MDA435/LCC6 cells MWXQdo9tcW[ncnH0bY9vKGG|c3H5 NWfjZWFJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOTEF2M{WvUGNEPiClZXzsd{BjgSCHTFnTRUwhUUN3ME2wMlA4QSEQvF2= MWexO|E2PDVyNR?=
human A549 cells NF;EW3hEgXSxdH;4bYPDqGG|c3H5 NVK5RmpxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkC4JO69VQ>? NIjnc5gyQTl4OEK1PC=>
Jurkat T lymphocytes NYPwOHRvS3m2b4TvfIlkyqCjc4PhfS=> Ml3yR5l1d3SxeHnjbZR6KGGpYXnud5QhUnW{a3H0JHQhdHmvcHjvZ5l1\XNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFgzPiEQvF2= M3K4SlE3OzZ4NkCy
human DU145 cells MlH3VJJwdGmoZYLheIlwdiCjc4PhfS=> NEL0PGg4OiCq NVrXRpBuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFkh|ryP MWqyNlI3ODF4Nh?=
human MDA-MB-231 cells MlSwVJJwdGmoZYLheIlwdiCjc4PhfS=> M1iwSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCkeTDYWHQh[XO|YYmsJGlEPTB;MD6wPVEh|ryP MWeyOVQ3PzJ7MR?=
human H1299 cells NILM[ZNRem:uaX\ldoF1cW:wIHHzd4F6 MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEhzMkm5JINmdGy|IHL5JHhVXCCjc4PhfUwhUUN3ME2wMlA6PiEQvF2= M17pWlI2PDZ5Mkmx
human HL60 cells NXW2VJRFS3m2b4TvfIlkyqCjc4PhfS=> NH;jTXk1QCCq NFj5O4JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSC2conwZY4h[my3ZTDzeIFqdmmwZz3iZZNm\CCqZX3vZ5l1d22ndILpZ{BidmGueYPpd{whT0l3ME2wMlEh|ryP M1XDSFI2QDd2M{O1
human LNCAP cells M4jwbWN6fG:2b4jpZ:Kh[XO|YYm= M3;BclQh\GG7cx?= MXXDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD1yLkGg{txO NG\UZZEzOjR6MES5OS=>
NCI-H69 cell line MWLQdo9tcW[ncnH0bY9vKGG|c3H5 MnvERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDkdpVoKHOnboPpeIl3\SCQQ1mtTFY6KGOnbHygcIlv\SCkeTDBcIFu[XJiQnz1[UBie3OjeTygTWM2OD1yLkGg{txO MYKxO|I5PjN7Mx?=
human A2780 cells M2j0XWN6fG:2b4jpZ:Kh[XO|YYm= M2XhclczKGh? NFTGdG1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF5NEmg{txO NYfsb3RbOTd6OUCwPVQ>
human HT-29 cells NF\RcWlRem:uaX\ldoF1cW:wIHHzd4F6 NHj4Zm86PiCq MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zM{Og{txO NFm4NWczPzd6NES5
B16 mouse melanoma cells MnXMR5l1d3SxeHnjxsBie3OjeR?= Mmn4R5l1d3SxeHnjbZR6KHSqYYSgZ4F2e2WmIHGgOVAmKHKnZIXjeIlwdiCrbjDhZpNwemKjbnPlJIF1KDR7MDDucUBqdiCEMU[gcY92e2VibXXsZY5wdWFiY3XscJMhfXOrbnegUXRUKGG|c3H5MEBGSzVyPUCuNVYh|ryP M165U|EyODJyMki1
human SKMES1 cells NV3iZ4FFWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFvV[WE4OiCq NX\sTWtSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT21GWzFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlE4KM7:TR?= M1jleFIzOjZyMU[2
human fibroblast (NHF) cells NYDlTmdiS3m2b4TvfIlkyqCjc4PhfS=> MlXxR5l1d3SxeHnjbZR6KHSqYYSgZ4F2e2WmIHGgOVAmKHKnZIXjeIlwdiCrbjDhZpNwemKjbnPlJIF1KDR7MDDucUBqdiCwb4LtZYwhcHWvYX6g[oljem:kbHHzeEApVkiIKTDj[YxteyC3c3nu[{BOXFNiYYPzZZktKEWFNUC9NE4zOiEQvF2= MoTBNVExOjB{OEW=
mouse L1210 cells NHG5b|hHfW6ldHnvckBie3OjeR?= M{fTRmlvcGmkaYTpc44hd2ZiUl7BJJN6dnSqZYPpd{BqdiCvb4Xz[UBNOTJzMDDj[YxteyxiRVS1NF0xNjJ|IN88US=> NIL3cpQ3QTB7OUm=
human NCI-H460 cells M{LLeGZ2dmO2aX;uJIF{e2G7 NVPBb2JzSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy|LDDJR|UxRTBwM{ig{txO MYWyNVU6QTByMB?=
human MCF7 cells NHfXUHJEgXSxdH;4bYPDqGG|c3H5 MUm0JIRigXN? NXzWbXh6S3m2b4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQh|ryP MnTtNlI1QDB2OUW=
human SF268 cells NHnWfpZHfW6ldHnvckBie3OjeR?= NXzO[mlrSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHNHOjZ6IHPlcIx{NCCLQ{WwQVAvPiEQvF2= MVWyNVU6QTByMB?=
human KB cells MkH2R5l1d3SxeHnjxsBie3OjeR?= Mn3ZOFghcA>? NX7jNGltS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlY1KM7:TR?= MXeyNFM3OzF2Mh?=
human HepG2 cells MVjDfZRwfG:6aXRCpIF{e2G7 NF\ZeFUzPCCq MmjKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VWyCjc4PhfUwhUUN3ME2wMlch|ryP MV[yNVA6PDB2OR?=
mouse L5178Y cells MXnDfZRwfG:6aXRCpIF{e2G7 MW[yOEBp MnHVR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFUyPzi\IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE44OiEQvF2= MUKyN|E6QTR5OR?=
human MCF7 cells NHrrXmlEgXSxdH;4bYPDqGG|c3H5 NFLzTog4OiCq M3TrUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHhVXCCjc4PhfUwhT0l3ME2wMlg3KM7:TR?= NFTEboIzODV7MU[3PC=>
human MRC5 cells MYTQdo9tcW[ncnH0bY9vKGG|c3H5 MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2UQ{WgZ4VtdHNuIFnDOVA:OC56ODFOwG0> NHTwblYzOTV7OUCwNC=>
MDA435/LCC6 cells M1GwcnBzd2yrZnXyZZRqd25iYYPzZZk> MkLHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDteYx1cWS{dXegdoV{cXO2YX70JG1FSTR|NT;MR2M3KGOnbHzzJIJ6KEWOSWPBMEBKSzVyPUCuPVc4KM7:TR?= MnO2NVcyPTR3MEW=
mouse NIH/3T3 cells M4THWmN6fG:2b4jpZ:Kh[XO|YYm= MkLyO|IhcA>? M{fsPGlvfHKrboPpZ{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy|IH;2[ZJmgHC{ZYPzbY5oKE2GUkGgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkCxJO69VQ>? MXGxPFk2PDB2MB?=
human Detroit 551 cells NIfUd2VEgXSxdH;4bYPDqGG|c3H5 MojnO|IhcA>? NUHjVpZNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTGW2cn;peEA2PTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHhVXCCjc4PhfUwhT0l3ME2xMlc4KM7:TR?= MUWyNFU6OTZ5OB?=
mouse DA-3 cells NX;i[Yk{S3m2b4TvfIlkyqCjc4PhfS=> NXPs[IpqOjRiaB?= MmfSR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSGEuOyClZXzsd{Bi\nSncjCyOEBpenNiYomgXHRVKGG|c3H5MEBKSzVyPUGuPUDPxE1? MkW3NlQ6ODB4Nki=
african green monkey Vero cells NIToUJREgXSxdH;4bYPDqGG|c3H5 Mmr1N{Bl[Xm| MlnRR5l1d3SxeHnjbZR6KGGpYXnud5Qh[W[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxRTJwNTFOwG0> MnHYNlExQTRyNEm=
Dx5 cell lines MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzUbIUh[2:vcH;1coQhf2G|IHX2ZYx2[XSnZDDmc5IhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGR5PSClZXzsJIxqdmW|IIXzbY5oKE2WVDDhd5NigSxiaXO1NF0zKM7:TR?= NY\IfGZDOTB4OUi0OFk>
human HeLa3 cell line MXzDfZRwfG:6aXRCpIF{e2G7 MoDDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[TNiY3XscEBtcW6nIHL5JG1VXCCjc4PhfUwhUUN3ME2yMlk3KM7:TR?= NFS2UXIyPjl2MkCzOy=>
mouse L5178Y cells MkP4R5l1d3SxeHnjxsBie3OjeR?= NV\lXWo{OjRiaB?= MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDMOVE4QFliY3XscJMh\XiycnXzd4lv\yCyLXfwJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Nz63N{DPxE1? MmPpNlMyQTl2N{m=
human CRL7761 cells MnP4R5l1d3SxeHnjxsBie3OjeR?= MlzuN{Bl[Xm| NHK1Vo9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEWkx5N{[xJINmdGy|IHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVA:OTBwNTFOwG0> MUWyNVA6PDB2OR?=
human A2780/ADR cells NF3tT3dEgXSxdH;4bYPDqGG|c3H5 M1fKdFczKGh? MlyxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBxQVTSJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OThwNkKwPUDPxE1? M{nWVlE4QDlyMEm0
human SKOV3 cells M3OyVmN6fG:2b4jpZ:Kh[XO|YYm= MVOyOEBp NVrIOJFrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFiWVDDhd5NigSxiSVO1NF0zOC54IN88US=> NUXZdVl6OjR7MEC2Olg>
human ES2 cells NWCwUm0zS3m2b4TvfIlkyqCjc4PhfS=> MmLSNlQhcA>? Mnu4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSXMzKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDYWHQh[XO|YYmsJGlEPTB;MkWuOUDPxE1? MlrmNlQ6ODB4Nki=
CEM cells NHvDU5pEgXSxdH;4bYPDqGG|c3H5 NInI[5o4OiCq MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBETU1iY3XscJMh[W[2ZYKgO|IhcHK| MlLaNVc3ODh|OU[=
HOS cells NGPVZZZEgXSxdH;4bYPDqGG|c3H5 NIjG[4w4OiCq MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBJV1NiY3XscJMh[W[2ZYKgO|IhcHK| MV2xO|YxQDN7Nh?=
mouse DA-3 cells MmfhR5l1d3SxeHnjxsBie3OjeR?= M2nLO|IxKM7:TR?= M{LSdlYxKG2rboO= NFuzNmZEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBFSS1|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEAzOCC3TTDh[pRmeiB4MDDtbY5{KGK7IGjUWEBie3OjeR?= NV31dnk5OjR7MEC2Olg>
human G361 cells MkX6R5l1d3SxeHnjxsBie3OjeR?= NVv4e5BTPzJiaB?= NHH3[3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIOzZzIHPlcIx{KGGodHXyJFczKGi{cx?= MVexO|YxQDN7Nh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Chk1 / Chk1 / p-ATR / ATR ; 

PubMed: 26727128     


After Caco-2 cells were treated with or without 1 μ M daunorubicin, whole cell extracts were collected at 1, 3, 6, 12, 24, and 48 h and immunoblotted for Chk1, p-Chk1, ATR, and p-ATR. β-actin served as the loading control.

26727128
Immunofluorescence
p-Chk1; 

PubMed: 26727128     


Caco-2 cells were treated with or without 1 μ M daunorubicin for 48 h, and then fixed and stained with anti-p-Chk1 antibody and DAPI. Images were collected under a fluorescence microscope. Scale bar = 10 μm. 

26727128
Growth inhibition assay
Cell viability; 

PubMed: 30745844     


(A) Viability of AML cell lines under different concentrations of Dnr according to the CCK-8 assay. (B) IC50 of AML cell lines calculated according to the result of the CCK-8 assay.

30745844

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (177.31 mM)
Water 100 mg/mL (177.31 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 563.98
Formula

C27H29NO10 . HCl

CAS No. 23541-50-6
Storage powder
in solvent
Synonyms Daunomycin HCl

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03878927 Recruiting Drug: CPX-351|Drug: Gemtuzumab Ozogamicin Acute Myeloid Leukemia Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer August 23 2019 Phase 1
NCT03896269 Recruiting Drug: Liposome-encapsulated Daunorubicin-Cytarabine Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 14 2019 Phase 1
NCT02914977 Active not recruiting Drug: Daunorubicin Acute Lymphocytic Leukemia|Acute Myeloid Leukemia Tara Lin|University of Kansas Medical Center November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Daunorubicin HCl | Daunorubicin HCl supplier | purchase Daunorubicin HCl | Daunorubicin HCl cost | Daunorubicin HCl manufacturer | order Daunorubicin HCl | Daunorubicin HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID